A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.Let’s suppose you’re a man, and you have had elevated PSA levels (prostate-specific antigen) for some time. This might indicate a prostate tumor. A so-called multi-parametric MRI scan would seem advisable. Those MRI images are assessed by a radiologist and given a PI-RADS *) score. Is there indeed a tumor present? If so, how aggressive is it? To determine this, a biopsy is usually performed, in which a small piece of tumor tissue is removed via a hollow needle.
The assessment of the different MRI images is done by humans. It requires a lot of experience to read these images as thoroughly and unambiguously as possible. Years ago, Tom Scheenen and his colleagues from the Radiology and Nuclear Medicine department wondered whether the information from these MRI images could also be assessed automatically through an objective calculation. The idea was to simply circle an anatomically suspect spot in the prostate on the images and then have the machine calculate whether the tissue is healthy or abnormal. And if so, have it objectively determine the severity and diagnose it.
Is it a tumor?
In Investigative Radiology, Scheenen and colleagues have now published research that shows that it is possible. In five different hospitals, MRI images were taken of a total of fifty patients based on a clear protocol. The patients followed the normal examination and treatment route, but it was also examined whether a proper analysis and diagnosis could be made on the basis of just the MRI images.
Researcher Tom Scheenen: “The MRI images of approximately half an hour long provide an enormous amount of information. Firstly, we can distinguish between normal tissue and abnormal tumor tissue. Secondly, we visualize the mobility of water in the abnormal tissue. We also look at how quickly contrast fluid leaks from the blood vessels in and around the tumor, and how it flows back and is absorbed.”
Flows and leaks
The latter two criteria provide information about the severity and aggressiveness of the tumor. Scheenen: "In tumor tissue, cells are packed closer together, and the normal structure between the cells is disturbed. This ensures that water in tumor tissue often encounters boundaries that it is less likely to pass through. The less mobile the water, the more aggressive the tumor. This can be easily visualized with so-called diffusion-weighted MRI, and captured in objective numbers.”
The leakage of contrast fluid from small blood vessels around the tumor is also an important criterion. Scheenen: "A tumor needs extra nutrition and oxygen to grow. To do this, it quickly but carelessly creates new blood vessels. The poor quality of these vessels causes the leakage of the contrast fluid, something that is not the case with normal blood vessels. In these case, the sooner the contrast medium leaks - and is then absorbed and removed - the more aggressive and dangerous the tumor.”
The MRI images not only make it possible to determine the presence of a prostate tumor but also to assess its severity and aggressiveness objectively. Moreover, the research they have now published shows that the results of the 50 patients in all five participating hospitals could have been assessed in the same way and would have led to the same results. Scheenen: “Our research shows that this approach works and that it is a valid, generally applicable method.” What are the benefits? “Any differences in assessment between radiologists can be prevented because we now have a technique to standardize and automate the assessment. Furthermore, in people with a tumor that is barely growing, checks can now be carried out with an MRI and without a biopsy.” To further investigate the power of the system, Scheenen is entering these and future data into DRE, the Digital Research Environment. "This way, the system will be available to radiologists all over the world, and we will probably be able to improve it even more, adding more data.”
Publication in Investigative Radiology: A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach - Marnix C. Maas, Geert J.S. Litjens, Alan J. Wright, Ulrike I. Attenberger, Masoom A. Haider, Thomas H. Helbich, Berthold Kiefer, Katarzyna J. Macura, Daniel J.A. Margolis, Anwar R. Padhani, Kirsten M. Selnæs, Geert M. Villeirs, Jurgen J. Fütterer, Tom W.J. Scheenen
*) PI-RADS scale for prostate MRI imaging:
The prostate MRI is assessed on a scale of 1 to 5. The scales indicate the risk of (clinically significant) cancer
- PI-RADS 1: very low (clinically significant cancer is highly unlikely to be present)
- PI-RADS 2: low (clinically significant cancer is unlikely to be present)
- PI-RADS 3: intermediate (the presence of clinically significant cancer is equivocal)
- PI-RADS 4: high (clinically significant cancer is likely to be present)
- PI-RADS 5: very high (clinically significant cancer is highly likely to be present)
More information (in Dutch):
Related news items
Rob ter Horst in Dutch television broadcast Brandpunt Plus21 May 2019
In a Dutch television broadcast, called Brandpunt Plus, Rob ter Horst, PhD candidate, theme Infectious diseases and global health, explains how he records data about himself and what he hopes to find out about himself.read more
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more